Thursday, August 18, 2022 10:09:45 AM
Gambit53
Understand and agree w/your sense of (WHAT ????). One positive point can be made about recent news...It does look like the Amyloid Plaque thesis people have just about entirely left the field. That matters b/c the entire food chain of insurance companies, memory clinics, dementia warehouses, and all the treatment/care centers now must begin to pack up and break camp. They must be in denial as the AVXL MOA eventually obviates their entire supply chain-system. That has to settle in...what is next to treat the seriously ill CNS patient and their families? NOT OUR PROBLEM ???? We'll see. AVXL did not create the existing CNS diseases treatment world but , like it or not, it's out there.
The fact that the massive CNS disease patient base and existing science shortfalls exist must be at least acknowledged. We better be ready to act when we open that Bag of Shat. IMO. That is the issue(s) that Dr.M. and AVXL staff must be ready to deal with next. Obviously, the existing suppliers do not know yet what is about to hit them nor how to deal with it in a positive manner. That includes WS. . IMO.
By this time something should have leaked somewhere if we were getting spectacular results. Don’t think it would be humanly possible to bottle up those kinds of results when you’re dealing with desperate people
Understand and agree w/your sense of (WHAT ????). One positive point can be made about recent news...It does look like the Amyloid Plaque thesis people have just about entirely left the field. That matters b/c the entire food chain of insurance companies, memory clinics, dementia warehouses, and all the treatment/care centers now must begin to pack up and break camp. They must be in denial as the AVXL MOA eventually obviates their entire supply chain-system. That has to settle in...what is next to treat the seriously ill CNS patient and their families? NOT OUR PROBLEM ???? We'll see. AVXL did not create the existing CNS diseases treatment world but , like it or not, it's out there.
The fact that the massive CNS disease patient base and existing science shortfalls exist must be at least acknowledged. We better be ready to act when we open that Bag of Shat. IMO. That is the issue(s) that Dr.M. and AVXL staff must be ready to deal with next. Obviously, the existing suppliers do not know yet what is about to hit them nor how to deal with it in a positive manner. That includes WS. . IMO.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
